Loading
Latest filing published 19 May 2026 for Innovent Biologics, Inc., €418k.
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Zieziula Gary Joseph is a declared insider of Innovent Biologics, Inc. (chief executive), with filings sourced from HKEX. We count 6 filings; the first trade dates from 1 June 2022 and the latest from 14 May 2026.
The open-market side counts 5 purchases alongside 1 sale for €418k. The totals do not cover 5 filings with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Since January 2026: 1 purchase and 1 sale on the market.
On 19 May 2026 came the latest disclosure, an open-market sale for €418k in Innovent Biologics, Inc. The clock since the last published purchase (2 April 2026) now reads 206 days. The median gap between a trade and its publication by HKEX is 5 days. The shorter that gap, the sooner other investors can see what insiders have done. Every figure here comes from the filings published by HKEX and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations